Impulse Dynamics announced today that it raised $136 million in financing to accelerate its investment in its heart failure therapy.
Perceptive Advisors, Redmile Group, Alger and Hobart Healthcare led the financing round. The company expects it to accelerate investment in global commercialization, technology, product innovation and clinical evidence development.
Marlton, New Jersey–based Impulse Dynamics plans to use funds to support, among other things, its INTEGRA-D and AIM HIGHer trials. The company develops the Optimizer Smart Mini system to deliver cardiac contractility modulation (CCM) therapy to the heart. It significantly improves heart contraction to allow more oxygen-rich blood to push out through the body.
INTEGRA-D evaluates the combination of the company’s proprietary CCM therapy with implantable cardioverter defibrillator (ICD) therapy. All this comes through a single device — the Impulse Dynamics Optimizer Integra CCM-D system.<…